Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Seasonal Flu Vaccine in Adults 18-64 Years
NCT07851246Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza (4 arms), sponsored by GSK. Primary endpoints: Geometric Mean Titer of Antigen 1 at Day 29, Geometric Mean Titer of Antigen 2 at Day 29 and 7 more. Started Oct 2026; status: recruiting.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT07851246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07851246.